The benefits of lowering blood pressure (BP) in hypertension, as well as in patients with diabetes, chronic renal disease or with a high cardiovascular (CV) risk profile, have been consistently demonstrated. Further clinical trials have explored the influence of BP levels in the lower range on the incidence of CV events, while some others have designed to evaluate the potential benefits obtained with an intensive antihypertensive therapy, aimed at achieving a target systolic BP levels below 120 mm Hg on major CV events among high-risk individuals with type 2 diabetes, as compared to that obtained from a standard therapy. Taken together, the results of several recent randomized clinical trials (RCTs) have challenged the currently prevailing paradigm "the lower, the better" in the hypertension management and have somehow revitalized the concept of the J-curve with respect to relations between BP levels and coronary events. In fact, detailed analyses showed an increased risk of coronary events, mostly myocardial infarction, in those patients who achieved the lowest BP levels, particularly in high-risk subsets of hypertensive patients. The same trials, however, confirmed the benefits of BP reductions even below 120 mm Hg on stroke incidence. In the present article, we revisited the main findings of some recent large clinical trials performed in hypertension and in high-risk individuals. Our conclusions highlight the importance of a closer scrutiny for coronary artery disease and suggest caution in lowering BP levels aggressively in patients with high-risk profile or diabetes.

Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials / Volpe, Massimo; Tocci, Giuliano. - In: AMERICAN JOURNAL OF HYPERTENSION. - ISSN 0895-7061. - 24:10(2011), pp. 1060-1068. [10.1038/ajh.2011.105]

Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials

VOLPE, Massimo;TOCCI, GIULIANO
2011

Abstract

The benefits of lowering blood pressure (BP) in hypertension, as well as in patients with diabetes, chronic renal disease or with a high cardiovascular (CV) risk profile, have been consistently demonstrated. Further clinical trials have explored the influence of BP levels in the lower range on the incidence of CV events, while some others have designed to evaluate the potential benefits obtained with an intensive antihypertensive therapy, aimed at achieving a target systolic BP levels below 120 mm Hg on major CV events among high-risk individuals with type 2 diabetes, as compared to that obtained from a standard therapy. Taken together, the results of several recent randomized clinical trials (RCTs) have challenged the currently prevailing paradigm "the lower, the better" in the hypertension management and have somehow revitalized the concept of the J-curve with respect to relations between BP levels and coronary events. In fact, detailed analyses showed an increased risk of coronary events, mostly myocardial infarction, in those patients who achieved the lowest BP levels, particularly in high-risk subsets of hypertensive patients. The same trials, however, confirmed the benefits of BP reductions even below 120 mm Hg on stroke incidence. In the present article, we revisited the main findings of some recent large clinical trials performed in hypertension and in high-risk individuals. Our conclusions highlight the importance of a closer scrutiny for coronary artery disease and suggest caution in lowering BP levels aggressively in patients with high-risk profile or diabetes.
2011
antihypertensive treatment; blood pressure; blood pressure targets; coronary artery disease; high blood pressure; high cardiovascular risk; hypertension; j-curve
01 Pubblicazione su rivista::01a Articolo in rivista
Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials / Volpe, Massimo; Tocci, Giuliano. - In: AMERICAN JOURNAL OF HYPERTENSION. - ISSN 0895-7061. - 24:10(2011), pp. 1060-1068. [10.1038/ajh.2011.105]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/381156
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact